Cargando…
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2–73.3%), and the median progression-free survival was 8.8 months. There were no gra...
Autores principales: | Petrioli, R, Sabatino, M, Fiaschi, A I, Marsili, S, Pozzessere, D, Messinese, S, Correale, P, Civitelli, S, Tanzini, G, Tani, F, De Martino, A, Marzocca, G, Lorenzi, M, Giorgi, G, Francini, G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409570/ https://www.ncbi.nlm.nih.gov/pubmed/14735168 http://dx.doi.org/10.1038/sj.bjc.6601521 |
Ejemplares similares
-
Reply: UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Francini, G, et al.
Publicado: (2004) -
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Alliot, C
Publicado: (2004) -
Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer
por: Sheikh, H Y, et al.
Publicado: (2008) -
Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer
por: Delord, J-P, et al.
Publicado: (2007) -
A phase I study of oral UFT/leucovorin and irinotecan, plus radiation for locally recurrent rectal cancer
por: Ikeda, Masataka, et al.
Publicado: (2018)